Company Description
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.
The company’s lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma.
It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia.
Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Michael Myers |
Contact Details
Address: 42127 Pleasant Forest Court Ashburn, Virginia 20148-7349 United States | |
| Phone | 703 980 4182 |
| Website | quoinpharma.com |
Stock Details
| Ticker Symbol | QNRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671502 |
| CUSIP Number | 74907L409 |
| ISIN Number | US74907L4095 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Myers Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Denise Carter | Co-Founder, Chief Operating Officer and Director |
| Sally Lawlor | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | 424B3 | Prospectus |
| Dec 4, 2025 | EFFECT | Notice of Effectiveness |
| Nov 17, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 7, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Oct 27, 2025 | SCHEDULE 13G | Filing |
| Oct 23, 2025 | D | Notice of Exempt Offering of Securities |
| Oct 21, 2025 | 8-K | Current Report |